EU/3/15/1547: Orphan designation for the treatment of narcolepsy



On 9 October 2015, orphan designation (EU/3/15/1547) was granted by the European Commission to NeuroLifeSciences, France, for mazindol for the treatment of narcolepsy.

Key facts

Active substance
Intended use
Treatment of narcolepsy
Orphan designation status
EU designation number
Date of designation

Propharma Group The Netherlands B.V.
Schipholweg 73
2316 ZL Leiden

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

Date Update
August 2022 The sponsorship was transferred from IDEA Innovative Drug European Associates (Ireland) Limited, Ireland to Propharma Group The Netherlands B.V., Netherlands in August 2022.
July 2022 The sponsor’s address was updated in July 2022.
February 2020 The sponsorship was transferred to IDEA Innovative Drug European Associates (Ireland) Limited, Ireland, in February 2020.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating